LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Newly Developed Point-of-Care Hemoglobinometer Evaluated

By LabMedica International staff writers
Posted on 10 Dec 2014
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Hemoglobin (Hb) concentration is routinely measured using automated analyzers, and although these counters are very accurate and reliable, they are expensive and too cumbersome for portability.

Portable hemoglobinometer can potentially provide the solution to the challenges as they are affordable, precise, and convenient and require only a tiny sample of capillary or venous blood, do not require any calibration and display digital results immediately.

Scientists at the Indian Institute of Technology Delhi (IITD; New Delhi, India) collected 200 hundred randomly selected venous blood samples, submitted for hemogram study at the Department of Hematology, All India Institute of Medical Sciences (New Delhi, India). The hemoglobin values of these samples were evenly spread. There were 67, 76, and 57 samples in the ranges of 3.4–8 g/dL, 8–12.5 g/dL, and 12.5–20 g/dL respectively.

The investigators evaluated the performance of the portable hemometer called TrueHb (New Delhi, India) developed by IITD, and compared it with an automated five-part hematology analyzer intended for in vitro diagnostic use in clinical laboratories, the Sysmex counter XT 1800i (Sysmex; Kobe, Japan). The two set of values were comparatively analyzed and the repeatability of the performance of TrueHb was also evaluated against Sysmex value.

The scatter plot of TrueHb values and Sysmex values showed linear distribution with positive correlations. The intraclass correlation (ICC) values between the two set of values was found to be very high. The mean difference in Bland–Altman plots of TrueHb values against the Sysmex values was found to be −0.02, with limits of agreement between -0.777 and 0.732 g/dL. Statistical analysis suggested good repeatability in results of TrueHb, having a low mean coefficient of variation (CV) of 2.22, against 4.44, that of Sysmex values, and 95% confidence interval of 1.99 to 2.44, against 3.85 to 5.03, that of Sysmex values.

The authors concluded that a strong positive correlation between the two measurements devices suggest that the newly developed hemometer, TrueHb, can potentially replace a pathology laboratory analyzer for the purpose of measuring hemoglobin in blood samples. Keeping the performance of TrueHb in view, the newly developed device exhibited the potential to become a dependable tool for healthcare providers for measuring and monitoring hemoglobin levels of patients in conventional healthcare setups as well as in field studies. The study was published on November 22, 2014, in the International Journal of Laboratory Hematology.

Related Links:
Indian Institute of Technology Delhi 
All India Institute of Medical Sciences
TrueHb



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automatic CLIA Analyzer
Shine i9000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more